Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Anthony Mack Biography and Net Worth

CEO of Virpax Pharmaceuticals

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of ProSolus Pharmaceuticals and Scilex Pharmaceuticals. Mr. Mack has utilized his skills and experience to implement corporate governance policies and overall business strategy by serving on executive boards. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

What is Anthony P. Mack's net worth?: The estimated net worth of Anthony P. Mack is at least $8,334.48 as of May 18th, 2022. Mr. Mack owns 25,256 shares of Virpax Pharmaceuticals stock worth more than $8,334 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Mack may own. Learn More about Anthony P. Mack's net worth.
How do I contact Anthony P. Mack?: The corporate mailing address for Mr. Mack and other Virpax Pharmaceuticals executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Virpax Pharmaceuticals can also be reached via phone at 610-727-4597 and via email at [email protected]. Learn More on Anthony P. Mack's contact information.
Has Anthony P. Mack been buying or selling shares of Virpax Pharmaceuticals?: Anthony P. Mack has not been actively trading shares of Virpax Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, May 18th, Anthony P. Mack bought 7,575 shares of Virpax Pharmaceuticals stock. The stock was acquired at an average cost of $13.40 per share, with a total value of $101,505.00. Following the completion of the transaction, the chief executive officer now directly owns 25,256 shares of the company's stock, valued at $338,430.40. Learn More on Anthony P. Mack's trading history.
Who are Virpax Pharmaceuticals' active insiders?: Virpax Pharmaceuticals' insider roster includes Anthony Mack (CEO), and Jerrold Sendrow (Director). Learn More on Virpax Pharmaceuticals' active insiders.

Anthony P. Mack Insider Trading History at Virpax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/18/2022	Buy	7,575	$13.40	$101,505.00	25,256
11/18/2021	Buy	2,512	$39.90	$100,228.80

Anthony P. Mack Buying and Selling Activity at Virpax Pharmaceuticals

Virpax Pharmaceuticals Company Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Today's Range

Now: $0.33

$0.32

$0.37

50 Day Range

MA: $0.54

$0.30

$0.76

2 Week Range

Now: $0.33

$0.29

$5.48

Volume

970,033 shs

Average Volume

2,474,614 shs

Market Capitalization

$1.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89